Can-Fite BioPharma's A3AR Agonists Secures Brazilian Patent For Sexual Dysfunction Treatment

(RTTNews) - Can-Fite BioPharma Ltd. (CANF), Friday announced that the Brazilian Patent Office has granted patent entitled Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction.

Following this, the granted patent provides intellectual-property protection in Brazil for the use of Can-Fites proprietary A3AR agonists in the treatment of sexual dysfunction.

The patent reflects the company's broader clinical and preclinical programs, which is expected to help create future partnering or commercialization opportunities in Latin America.

In the pre-market hours, CANF is trading at $0.24, down 1.94 percent on the New York Stock Exchange American.